Expression of IL-17and IL-23 in Patients with B-cell non-HodgkinLymphoma Treated by RCHOP
- VernacularTitle:IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达
- Author:
Ying HUANG
;
Yihan LIU
;
Chengping LI
;
Kun WU
;
Yun ZENG
- Keywords:
Non-Hodgkin lymphoma;
Interleukin-17;
Interleukin-23;
Rituximab;
Prognosis
- From:
Journal of Kunming Medical University
2016;37(12):76-81
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To study the role of IL-17 and IL-23 in non-Hodgkin lymphoma (NHL) by detecting the expression levels of IL-17 and IL-23 in peripheral blood of B-cell non-Hodgkin lymphoma patients treated by RCHOP.Methods T wenty-five patients with B-cell NHL who achieved remission after 6 to 8 cycles of R-CHOP as a NHL group,20 healthy volunteers were recruited as a normal control group.RT-PCR was used to detect the expression levels of IL-17 mRNA and IL-23mRNA in NHL patients and health volunteers.Results The expression level of IL-17mRNA andIL-23 mRNAin the patients with NHL before therapy and the patients with NHL who achieved remission was lower than that in the normal control group (P＜0.05).The expression level of IL-17mRNA andIL-23mRNA in the patients with NHL who achieved remission was higher than that in the patients with NHL before therapy (P=0.001,P＜0.05).Conclusion IL-17 and IL-23mRNA expressions are higher after treated with R-CHOP.The expression levels of IL-17 mRNA and IL-23 mRNA in NHL patients are related with prognosis and efficacy.
